Editorial: safety of prenatal exposure to anti-TNF therapy on postnatal infectious complications

Aliment Pharmacol Ther. 2020 Oct;52(7):1216-1217. doi: 10.1111/apt.16029.

Authors

Dana Duricova^{1

2}, Katarina Mitrova^{1

3}

Affiliations

¹ IBD Clinical and Research Centre, ISCARE, a.s., Prague, Czech Republic.
² Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.

PMID: 33016561
DOI: 10.1111/apt.16029

No abstract available

Publication types

Editorial
Comment

MeSH terms

Child
Female
Humans
Immunotherapy
Infections*
Pregnancy
Prenatal Exposure Delayed Effects* / chemically induced
Risk Factors
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor-alpha